Is BARD1 p.Ser231Phe (c.692C>T) pathogenic?

BARD1 p.Ser231Phe (c.692C>T) is classified Uncertain significance in BARD1 (ClinVar, Multiple submitters, 7 submitters; last evaluated 2026-01-31). AlphaMissense: likely benign (0.1222); Very rare (popmax 0.00685%, afr); Associated with BARD1-related cancer predisposition.

What condition is associated with BARD1 p.Ser231Phe (c.692C>T)?

BARD1 p.Ser231Phe (c.692C>T) is associated with BARD1-related cancer predisposition, hereditary neoplastic syndrome, hereditary breast carcinoma (ClinVar).

How common is BARD1 p.Ser231Phe (c.692C>T) in the general population?

BARD1 p.Ser231Phe (c.692C>T) is very rare (popmax 0.00685%, afr) (gnomAD).

What do computational predictors say about BARD1 p.Ser231Phe (c.692C>T)?

AlphaMissense predicts likely benign (score 0.1222) — an in-silico prediction, not a clinical call.

BARD1 p.Ser231Phe

c.692C>T · rs758140052 · VCV237842

Uncertain significance Multiple submitters

Classification

Uncertain significance

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 7 submitters

AlphaMissense

likely benign

0.1222 · ACMG-weighted

gnomAD v4.1

Rare

very rare (popmax 0.00685%, afr)

Missense predictors

0/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

BARD1-related cancer predisposition

Computational evidence

Protein change
AlphaMissense	0.1222	likely benign
REVEL	0.072	moderately benign-leaning
SaProt	LLR -7.48	tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 2.1	GERP 0.57, phastCons 0.97
Regional constraint	o/e 1.06	unconstrained · MANE · 81 kb · p 0.077 · regional, not allelic
Overall
CADD	16.76	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.00685% African / African-American · 5/73,040 alleles

Filtering AF 0.0026% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.00177%

Overall 0.00252% 40/1,586,876 alleles · very rare

Ancestry group	Frequency	1 in
African / African-Americangrpmax	0.00685%	14,608
Remaining individualsnot grpmax-eligible	0.00327%	30,601
European (non-Finnish)	0.00281%	35,531

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: BARD1
Protein: p.Ser231Phe
Coding: c.692C>T
MANE Select: NM_000465
dbSNP: rs758140052
Type: single nucleotide variant
Location: chr2:214781182 (GRCh38)
Gene constraint: LOEUF 1.087 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Structure: AlphaFold pLDDT 64.82 · 11 PDB

Full BARD1 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

Also linked: hereditary neoplastic syndrome hereditary breast carcinoma

Similar variants

BARD1 p.Ser231= Benign/Likely benign ★★ same residue
BARD1 p.Ser231Cys Uncertain significance ★ ⚠ same residue
BARD1 p.Ser231Thr Uncertain significance ★ ⚠ same residue
BARD1 p.Ser231fs Pathogenic ★ same residue
BARD1 c.1314+1G>A Pathogenic/Likely pathogenic ★★ same condition
BARD1 c.1314+1G>T Likely pathogenic ★★ same condition
BARD1 c.1396-1G>A Likely pathogenic ★★ same condition
BARD1 c.1396-1G>C Likely pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/bard1-p-ser231phe (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown